Global Industry Analysts, Inc., April 2010, Pages: 752
-4
Table 3: Monthly Cost of Select Non-Hodgkin’s Lymphoma
Treatments (2009) II-4
Sales of Zevalin to Gain Momentum II-5
Combination Drugs - A Potential Winning Option for Manufacturers II-5
Existing
GlobalData, Jan 2010, Pages: 84
Non-Hodgkin’s Lymphoma (NHL) - DrugPipeline Analysis and Market Forecasts to 2015
Summary
GlobalData, the industry analysis specialist, has released a new report on the Pharmaceutical
Life Science Analytics, March 2011, Pages: 737
Non-HodgkinLymphoma Therapy Area PipelineReport contains detailed information on the non-hodgkinlymphomadrugpipeline. This report provides insight into the pipeline status of non-hodgkin
GlobalData, Nov 2010, Pages: 83
Non-Hodgkin’s Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist has released a new report, “Non-Hodgkin’s Lymphoma (NHL
Bioseeker, May 2011, Pages: 954
assessment methodology to stratify the lymphomapipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of lymphomadrugs
GBI Research, Dec 2010, Pages: 126
.3.2 Breast Cancer 70
6.3.3 Colorectal Cancer 71
6.3.4 Non-Hodgkin’s Lymphoma 72
6.3.5 Prostate Cancer 73
6.4 Key Late Stage PipelineDrugs 74
6.4.1 Lung Cancer 74
6.4.2 Breast Cancer 75
6.4.3 Colorectal Cancer
Datamonitor, April 2010, Pages: 243
Upcoming related reports
1. Pipeline Overview and Dynamics
Key findings
Pipeline overview
Pipeline summary
The majority of drugs in late-phase development for lymphoma and multiple myeloma
Bioseeker, June 2009, Pages: 535
and Stage of Development
Figure 14: Breakdown of the Non-Hodgkin’s LymphomaPipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 15: Breakdown
GlobalData, Oct 2011, Pages: 136
Non-Hodgkin's Lymphoma (NHL) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Non-Hodgkin
Datamonitor, Dec 2009, Pages: 187
Incorporation of pipelinedrugs into treatment
Velcade (Millennium/Johnson & Johnson)
The combination of Velcade with Rituxan is active in the first-line treatment of indolent non-Hodgkin's lymphomas (NHL
Global Markets Direct, Feb 2011, Pages: 209
pipeline. This report provides information on the therapeutic development for Non-HodgkinLymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews
Global Markets Direct, Dec 2010, Pages: 216
pipeline. This report provides information on the therapeutic development for Non-HodgkinLymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews
Global Markets Direct, Dec 2010, Pages: 45
Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies
Global Markets Direct, Sep 2011, Pages: 420
pipeline. This report provides information on the therapeutic development for Non-HodgkinLymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews
Bioseeker, Feb 2011
& Acquisition Through Pipeline Benchmarking
LymphomaDrug Development Strategies at Work - Define Your Competition
Hematological Cancers DrugPipeline Update 2011-
The Package Includes:
- A progress analysis
GBI Research, Dec 2011, Pages: 215
. The report provides an in-depth analysis of major oncology indications, which includes breast cancer, colorectal cancer, Non-Hodgkin’s Lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer
Global Markets Direct, Aug 2011, Pages: 194
Or Refractory Indolent Non-HodgkinsLymphoma
Jun 17, 2011: Allos Therapeutics Reports Encouraging results From Retrospective Analysis Of FOLOTYN In Patients With Relapsed Or Refractory Peripheral T-Cell
